Alnylam Pharmaceuticals Stock Alpha and Beta Analysis
| ALNY Stock | USD 328.16 3.08 0.93% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Alnylam Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Alnylam Pharmaceuticals over a specified time horizon. Remember, high Alnylam Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Alnylam Pharmaceuticals' market risk premium analysis include:
Beta 0.52 | Alpha (0.45) | Risk 2.31 | Sharpe Ratio (0.20) | Expected Return (0.46) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Alnylam Pharmaceuticals Analysis, Alnylam Pharmaceuticals Valuation, Alnylam Pharmaceuticals Correlation, Alnylam Pharmaceuticals Hype Analysis, Alnylam Pharmaceuticals Volatility, Alnylam Pharmaceuticals Price History and analyze Alnylam Pharmaceuticals Performance. Alnylam Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Alnylam Pharmaceuticals market risk premium is the additional return an investor will receive from holding Alnylam Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Alnylam Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Alnylam Pharmaceuticals' performance over market.| α | -0.45 | β | 0.52 |
Alnylam Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Alnylam Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Alnylam Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Alnylam Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Alnylam Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Alnylam Pharmaceuticals shares will generate the highest return on investment. By understating and applying Alnylam Pharmaceuticals stock market price indicators, traders can identify Alnylam Pharmaceuticals position entry and exit signals to maximize returns.
Alnylam Pharmaceuticals Return and Market Media
The median price of Alnylam Pharmaceuticals for the period between Sun, Nov 9, 2025 and Sat, Feb 7, 2026 is 400.59 with a coefficient of variation of 9.86. The daily time series for the period is distributed with a sample standard deviation of 39.96, arithmetic mean of 405.34, and mean deviation of 33.38. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | MicroStrategy retains place in key index despite delisting threats | 12/15/2025 |
2 | Insider Trading | 01/05/2026 |
3 | Alnylam Pharmaceuticals CEO on Development Goals, Profitability | 01/13/2026 |
4 | NorthCrest Asset Manangement LLC Takes 738,000 Position in Alnylam Pharmaceuticals, Inc. ALNY | 01/22/2026 |
5 | Wells Fargo Raises Alnylam Revenue Estimates for Amvuttra Despite Projected Margin Compression | 01/27/2026 |
6 | Alnylam Pharmaceuticals Projects 2026 Revenue Around 5.3 Billion as It Focuses on a New Five-Year Strategy | 01/29/2026 |
7 | A Look At Alnylam Pharmaceuticals Valuation After New Revenue Outlook And Long Term Growth Targets | 02/04/2026 |
8 | Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Dont | 02/06/2026 |
About Alnylam Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Alnylam or other stocks. Alpha measures the amount that position in Alnylam Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 5.59 | 3.66 | 3.29 | 3.46 | Days Of Inventory On Hand | 104.82 | 88.62 | 101.91 | 96.81 |
Alnylam Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Alnylam Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alnylam Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Alnylam Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Alnylam Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Alnylam Pharmaceuticals' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Alnylam Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.